Philips highest ranked medical technology company among Clarivate Top 100 Global Innovators

Rhea-AI Summary

Philips (NYSE: PHG) has been recognized as the highest-ranked medical technology company in Clarivate's Top 100 Global Innovators 2025, marking its 12th consecutive year on this prestigious list. The company invested approximately EUR 1.7 billion (over 9% of sales) in R&D during 2024, with a strong focus on AI and data innovation.

The company's commitment to healthcare innovation is demonstrated through several key AI-powered solutions:

• Philips CT 5300: Combines hardware, software, and AI for improved imaging accessibility
• SmartSpeed Precise MRI: Enables up to 3x faster scan times while maintaining image quality
• AI-enabled cardiovascular ultrasound platform: Features advanced automation tools
• New Azurion system: Enhanced image-guided therapy for neurovascular treatment

With approximately 67,800 employees and EUR 18 billion in 2024 sales, Philips continues to leverage advanced technology and clinical insights to deliver innovative healthcare solutions across more than 100 countries.

News Market Reaction

-0.34%

1 alert

-0.34% News Effect

On the day this news was published, PHG declined 0.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

March 12, 2025

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in the Top 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years.

Roy Jakobs, CEO of Royal Philips said: "At Philips, we’ve been innovating for over 130 years to improve people’s lives. Innovation is our fundamental strength, the reason why customers choose us as their strategic partner and a key value driver for our company. Our portfolio of patient- and people-centric innovations in hardware, software, AI and services drives healthcare productivity and empowers people to look after their health and well-being – delivering better care for more people."

In 2024, Philips invested approximately EUR 1.7 billion – or an industry leading >9% of sales – in research and development to help drive better care for more people. Philips is increasingly focusing its innovation efforts on the potential of data and AI, both in hospital settings and at home. As a leader in AI-related patent applications in healthcare, Philips dedicates around half of its R&D workforce to these fields. 

Examples of Philips’ AI-powered innovations that increase caregiver productivity and deliver better care for more people include:

• the Philips CT 5300, which combines innovative hardware, software, and AI to make high-quality screening, diagnostic, and interventional imaging accessible to more patients
• the latest SmartSpeed Precise MRI technology, which enables scans to be completed up to three times faster, significantly cutting scan times while maintaining exceptional image quality
• the next-generation AI-enabled cardiovascular ultrasound platform with advanced AI tools to advance cardiovascular imaging and increase automation and productivity
• the new Azurion image-guided therapy system and advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients 

The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. The full report can be found here.

For further information, please contact:

Ben Zwirs
Philips Global External Relations
Tel.: +31 61521 3446
E-mail: media@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Dual AI engines in SmartSpeed Precise
• CT 5300 with AI-enabled workflow
• Azurion neuro biplane
• AI-enabled cardiovascular ultrasound platform

FAQ

How much did Philips (PHG) invest in R&D during 2024?

Philips invested EUR 1.7 billion in R&D during 2024, representing over 9% of sales, with about half of its R&D workforce dedicated to AI and data innovation.

What are the key AI-powered innovations announced by Philips (PHG) in 2025?

Key innovations include the CT 5300, SmartSpeed Precise MRI technology, AI-enabled cardiovascular ultrasound platform, and the Azurion image-guided therapy system for neurovascular treatment.

What is Philips' (PHG) position in the Clarivate Top 100 Global Innovators 2025?

Philips ranked as the highest medical technology company in the Clarivate Top 100 Global Innovators 2025, maintaining its presence on the list for 12 consecutive years.

What were Philips' (PHG) key financial metrics for 2024?

Philips reported sales of EUR 18 billion in 2024 and employed approximately 67,800 people across more than 100 countries.

How does Philips' SmartSpeed Precise MRI technology improve patient care?

The SmartSpeed Precise MRI technology enables scans to be completed up to three times faster while maintaining exceptional image quality, improving patient experience and clinical efficiency.